AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (the “Company” or “Anebulo”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering ...
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results